Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2012-05-09 Investor Presentation
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Investor Presentation 15 pages 534.5KB
Investor Presentation Classification · 95% confidence The document is titled 'INVESTOR PRESENTATION' and contains detailed information about the company's new direction, acquisition plans, technology overview, business model, regulatory environment, development plans, and key personnel. It includes strategic and financial highlights aimed at investors, such as share issuance, capital raising, and intellectual property details. There are no full financial statements or quarterly/yearly financial results presented, nor is it a transcript of a call or a regulatory filing. The content is consistent with a presentation designed to inform investors about the company's strategy and prospects. Therefore, the document fits the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2012-05-09 English
Acquisition of Drug Delivery Platform and Share Placement 3 pages 138.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 1 May 2012 regarding the acquisition of a drug delivery platform and a share placement by Imugene Limited. It details the acquisition terms, the technology platform, commercialization strategy, board appointment, management team, funding, and shareholder meeting notice. The content focuses on corporate actions related to acquisition and capital raising, including share issuance and placement. There are no financial statements or detailed financial performance data, nor is this a transcript, report, or regulatory certification. The document is a corporate announcement about acquisition and financing activities, fitting the Capital/Financing Update category.
2012-04-30 English
CGP: Agreement reached with Imugene for sale of Linguet IP 3 pages 2.1MB
Regulatory Filings Classification · 70% confidence The document text is heavily garbled and does not contain any clear readable content or recognizable keywords related to specific financial filings. There are no identifiable regulatory bodies, form names, fiscal period dates, or document titles. The length of the document is 11,196 characters, which is sufficient for a substantive report, but the content is unintelligible. Given the lack of any discernible information, the document cannot be classified into any specific filing category with confidence. According to the fallback rule, when a document does not fit any specific category, it should be classified as Regulatory Filings (RNS).
2012-04-30 English
Quarterly Report and Appendix 4C 7 pages 230.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Shareholder Update' and includes detailed financial data for the quarter ended 31 March 2012. It contains a consolidated statement of cash flows, cash reconciliation, payments to directors, and other financial disclosures typical of a quarterly financial report. The presence of Appendix 4C, a standard Australian Securities Exchange (ASX) quarterly cash flow report, confirms this is a quarterly financial report. The document length is 9546 characters, which is substantial and contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2012
2012-04-29 English
Trading Halt 2 pages 29.0KB
Regulatory Filings
2012-04-29 English
Half Yearly Report and Accounts 20 pages 859.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half Year Financial Results and Operations Report' and references the six-month period ended 31 December 2011. It includes detailed financial data such as revenue, net loss, cash balance, and a comprehensive Directors' Report. The document contains financial statements including the Consolidated Statement of Comprehensive Income, Statement of Financial Position, and Notes to the Financial Statements. It also includes an Independent Review Report and Auditor's Independence Declaration, which are typical components of an interim or half-year financial report. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2012
2012-02-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.